Current location:

Oncology

Source: | Author:tpl-c262dff | Published time: 2022-08-24 | 913 Views | Share:

Translational analysis of a phase II trial: Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours

Solitary fibrous tumours (SFT) are soft tissue sarcomas molecularly defined by the presence of the NAB2::STAT6 intrachromosomal fusion gene. Recently, it was published that diffuse immunohistochemistry (IHC) expression of p53 was only found in patients with aggressive SFT and was associated with significantly shorter PFS. TP53 mRNA levels were significantly higher in the low-aggressive SFT group. Only in the highly aggressive SFT group, relatively higher levels of TP53 were significantly associated with shorter PFS. In the end, they concluded that diffuse p53 IHC expression and higher TP53 mRNA levels are associated with worse prognosis in the subset of aggressive SFT patients treated with pazopanib. 


Normalized expression levels of TP53 in the different SFT subgroups



Reference: Napolitano A, Moura DS, Hindi N, et al. Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial. Therapeutic Advances in Medical Oncology. January 2022. doi:10.1177/17588359221116155

  


You may also be interested in:

Macrophages Promote Tumor Metastasis